Session Name: Liver: Hepatocellular Carcinoma and Other Malignancies
Session Date & Time: None. Available on demand.
*Purpose: The successful applications of programmed death protein-1 (PD-1) inhibitors in cancer therapy has led to an expanding use of immunotherapy in oncolog Liver transplantation (LT) is considered the most effective treatment for end stage liver diseases (ESLD) including HCC. However, the applications of PD-1 inhibitors in cancer patients would be controversial with LT. In this article, we have firstly described the clinical characteristics, imaging findings, and outcomes of 5 LT patients who had a History of HCC and PD-1 Inhibition.
*Methods: Data of 5 cases who were diagnosed with HCC and received a LT after applications of PD-1 inhibition were analyzed. Doses and cycles of PD-1, preoperative and postoperative characteristics were compared and analyzed.
*Results: The mean time difference between the last treatment of PD-1 inhibition and LT was 63.80±18.26 days. One patient had a recurrence in liver, vertebrae and lungs after 7 months. All patients displayed normal liver function in the latest follow-up. No acute allograft rejections were occurred in all patients.
*Conclusions: PD-1 inhibitor may be safe to be used tin the treatment of HCC before LT when the time difference is sufficient. Further investigations are needed for any convincing results.
To cite this abstract in AMA style:Chen M, Chen Z, Lin X. Pilot Evaluation of Prognosis After Liver Transplantation in Patients with a History of Hepatocellular Carcinoma and Pd-1 Inhibition [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/pilot-evaluation-of-prognosis-after-liver-transplantation-in-patients-with-a-history-of-hepatocellular-carcinoma-and-pd-1-inhibition/. Accessed June 13, 2021.
« Back to 2021 American Transplant Congress